{"text_format":"3","workbook":"xls","n_sheets":1,"sheets":["FinalFile_Figure_INQ-5151633120"],"not_rendered":{"external_links":1,"defined_names":1},"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"FinalFile_Figure_INQ-5151633120","index":0,"n_rows":79,"n_cols":7,"rows_kept":79,"merged":[[1,2,1,3],[1,4,1,5],[1,6,2,6],[3,0,4,0],[5,0,6,0],[7,0,9,0],[10,0,11,0],[12,0,12,1],[13,0,14,0],[15,0,17,0],[18,0,20,0],[21,0,23,0],[24,0,28,0],[29,0,31,0],[32,0,37,0],[38,0,38,6],[42,0,43,0],[42,1,42,2],[42,3,42,4],[42,5,43,6],[43,1,43,2],[43,3,43,4],[46,1,46,2],[46,3,46,4],[46,5,46,6],[51,1,51,2],[51,3,51,4],[51,5,51,6],[69,0,70,0],[69,1,69,2],[69,3,69,4],[69,5,70,5],[71,5,75,5],[78,0,78,6]],"flags":["formulas_cached_only"]}
["Table 1 Patient characteristics"]
[null,null,"nab-PTX plus RAM",null,"PTX plus RAM",null,"P value"]
[null,null,"N = 113","%","N = 138","%"]
["Age","Median (range)","67 (25−84)",null,"69 (40−85)",null,0.16]
[null,">65",71,62.8,96,69.6,0.261]
["Sex","Male",78,69,88,63.8,0.381]
[null,"Female",35,31,50,36.2,0.381]
["ECOG PS",0,85,75.2,88,63.8,0.051]
[null,1,25,22.1,43,31.2,0.109]
[null,">2",3,2.7,7,5.1,0.261]
["Previous gastrectomy","Yes",35,31,41,29.7,0.828]
[null,"No",78,69,97,70.3,0.828]
["Recurrence during adjuvant chemotherapy",null,6,5.3,8,5.8,0.867]
["Time to progressive disease on first-line therapy","<6 months",75,66.4,78,56.5,0.112]
[null,">6 months",38,33.6,60,43.5,0.112]
["HER2","Positive",13,11.5,23,16.7,0.246]
[null,"Negative",99,87.6,112,81.1,0.165]
[null,"Unknown",1,0.9,3,2.2,0.39]
["Histology","Diffuse",69,61.1,82,59.4,0.792]
[null,"Intestinal",43,38.1,52,37.7,0.952]
[null,"Mix, Missing",1,0.9,4,2.9,0.254]
["Number of metastatic sites","0–1",60,54,62,44.9,0.198]
[null,2,33,28.3,48,36.2,0.347]
[null,">3",20,17.7,28,18.9,0.604]
["Metastatic site","Liver",32,28.3,46,33.3,0.393]
[null,"Lung",18,15.9,19,13.8,0.631]
[null,"Lymph node",54,47.8,74,53.6,0.358]
[null,"Peritoneum",70,61.9,80,58,0.523]
[null,"Others",13,11.5,26,18.8,0.11]
["Prior therapy","Fluoropyrimidine",113,100,138,100,"-"]
[null,"Platinum",107,94.7,130,94.2,0.867]
[null,"Trastuzumab",10,8.8,21,15.2,0.127]
["Ascites","None",59,52.2,75,54.3,0.736]
[null,"Small",22,19.5,20,14.5,0.293]
[null,"Moderate",14,12.4,15,10.9,0.708]
[null,"Massive",18,15.9,28,20.3,0.374]
[null,"None/small",81,71.7,95,68.8,0.625]
[null,"Moderate/massive",32,28.3,43,31.2,0.625]
["nab-PTX, nanoparticle albumin-bound paclitaxel; RAM, ramucirumab; HER2, human epidermal growth factor receptor 2; ECOG PS, Eastern Cooperative Oncology Group performance status"]
[]
[]
["Table 2 Adverse events"]
[null,"nab-PTX plus RAM",null,"PTX plus RAM",null,"P value"]
[null,"(N = 113)",null,"(N = 138)"]
[null,"Any grade (%)",">Grade 3 (%)","Any grade (%)",">Grade 3 (%)","Any grade",">Grade 3"]
["All adverse events","112 (99.1)","76 (67.3)","134 (97.1)","88 (63.8)",0.254,0.563]
["Hematological"]
["Neutropenia","91 (80.5)","64 (56.6)","108 (78.3)","76 (55.1)",0.659,0.804]
["Leukopenia","85 (75.2)","34 (30.1)","107 (77.5)","48 (34.8)",0.667,0.43]
["Anemia","105 (92.9)","8 (7.1)","112 (81.2)","19 (13.8)",0.007,0.089]
["Thrombocytopenia","43 (38.1)","6 (5.3)","35 (25.4)","4 (2.9)",0.031,0.258]
["Non-hematological"]
["Sensory neuropathy","72 (63.7)","2 (1.8)","51 (37.0)","0 (0.0)",0,0.202]
["Fatigue","42 (37.2)","1 (0.9)","33 (23.9)","0 (0.0)",0.022,0.45]
["Anorexia","33 (29.2)","1 (0.9)","29 (21.0)","1 (0.7)",0.134,0.699]
["Nausea","17 (15.0)","2 (1.8)","18 (13.0)","1 (0.7)",0.649,0.425]
["Diarrhea","7 (6.2)","0 (0.0)","14 (10.1)","0 (0.0)",0.261,"-"]
["Stomatitis","10 (8.8)","0 (0.0)","14 (10.1)","1 (0.7)",0.728,0.55]
["Edema","33 (29.2)","0 (0.0)","32 (23.2)","0 (0.0)",0.279,"-"]
["Proteinuria","30 (26.5)","3 (2.7)","29 (21.0)","2 (1.4)",0.304,0.406]
["Hypertension","30 (26.5)","15 (13.3)","27 (19.6)","9 (6.5)",0.189,0.07]
["Febrile neutropenia","6 (5.1)","6 (5.1)","13 (9.4)","13 (9.4)",0.221,0.221]
["Interstitial pneumonia ","8 (7.1)","3 (2.7)","5 (3.6)","3 (2.2)",0.219,0.56]
["Hypersensitivity reaction","0 (0.0)","0 (0.0)","2 (1.4)","2 (1.4)","-","-"]
["nab-PTX, nanoparticle albumin-bound paclitaxel; RAM, ramucirumab; "]
[]
[]
[]
["Table 3 Overall response"]
["Best response","nab-PTX plus RAM",null,"PTX plus RAM",null,"P value"]
[null,"N = 83","%","N = 106","%"]
["CR",0,0,0,0]
["PR",28,33.7,29,27.4]
["SD",40,48.2,42,39.6]
["PD",11,13.3,28,26.4]
["NE",4,4.8,7,6.6]
["ORR",28,33.7,29,27.4,0.385]
["DCR",68,81.9,71,67,0.016]
["nab-PTX, nanoparticle albumin-bound paclitaxel; RAM, ramucirumab; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluated; ORR, overall response rate; DCR, disease control rate"]